DaVita Inc. (DVA)

In the past six months, DaVita's stock price has experienced some fluctuations. A ransomware attack and a severe flu season in 2025 triggered near-term volatility. In February 2025, DaVita announced robust improvement in its top and bottom lines for the fourth quarter of 2024, but there was a per-day decrease in total U.S. dialysis treatments sequentially. In July 2025, DaVita amended its credit agreement with a $250 million loan. In May 2025, DaVita announced the upsize and pricing of a private offering of 6.750% senior notes due 2033.

While specific detailed information on demand seasonality for all DaVita products and services is limited, the impact of the flu season on dialysis treatment volumes is noted as a temporary and cyclical issue. Demand for dialysis services typically stabilizes as the flu season wanes.

DaVita Inc. is a healthcare provider specializing in kidney care and dialysis services. Its core business involves providing care for patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). DaVita's major products and services include dialysis services, integrated kidney care, laboratory services, ancillary services and strategic initiatives, clinical research, digital health, pharmaceuticals and medical devices, and nephrology practice solutions.

DaVita has a significant global presence, operating 3,166 outpatient dialysis centers worldwide as of December 31, 2024, serving approximately 281,100 patients. In the United States, DaVita had 2,657 centers serving around 200,800 patients. Internationally, they operated 509 centers across 13 other countries, serving approximately 80,300 patients. DaVita has expanded its international operations through acquisitions, including an agreement in March 2024 to expand in Brazil and Colombia and enter Chile and Ecuador, aiming to become the largest dialysis services provider in Latin America. The company also has a presence in countries like Germany, China, and India.

DaVita generally maintains a strong brand reputation for providing high-quality dialysis services and is recognized as a leader in clinical quality and innovation. However, DaVita's reputation has been negatively impacted by legal challenges, resulting in approximately $1,000 million in payments, and there are ongoing investigations concerning donations and obstruction to competence.

DaVita Inc. has a significant institutional ownership. As of December 31, 2024, institutional investors held a substantial stake, with a total of 77,934,665 shares. Major institutional owners include Berkshire Hathaway Inc., Vanguard Group Inc., BlackRock, Inc., State Street Corp, Invesco Ltd., Morgan Stanley, Geode Capital Management, Llc, LSV Asset Management, Northern Trust Corp, and Dimensional Fund Advisors Lp. Individual ownership accounts for approximately 4.87% of the shares.